Success Metrics

Clinical Success Rate
85.7%

Based on 12 completed trials

Completion Rate
86%(12/14)
Active Trials
3(16%)
Results Posted
58%(7 trials)
Terminated
2(11%)

Phase Distribution

Ph phase_4
1
5%
Ph phase_2
8
42%
Ph phase_3
2
11%
Ph phase_1
5
26%

Phase Distribution

5

Early Stage

8

Mid Stage

3

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
5(31.3%)
Phase 2Efficacy & side effects
8(50.0%)
Phase 3Large-scale testing
2(12.5%)
Phase 4Post-market surveillance
1(6.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

12 of 15 finished

Non-Completion Rate

20.0%

3 ended early

Currently Active

3

trials recruiting

Total Trials

19

all time

Status Distribution
Active(3)
Completed(12)
Terminated(3)
Other(1)

Detailed Status

Completed12
Terminated2
Recruiting2
unknown1
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
3
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (31.3%)
Phase 28 (50.0%)
Phase 32 (12.5%)
Phase 41 (6.3%)

Trials by Status

completed1263%
unknown15%
terminated211%
recruiting211%
active_not_recruiting15%
withdrawn15%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT05139017Phase 2

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Recruiting
NCT07192770

G-CSF-Induced Bone Pain and Supportive Care Approaches

Completed
NCT05753618Phase 4

Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy

Recruiting
NCT03674411Phase 2

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Active Not Recruiting
NCT04240002Phase 1

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Terminated
NCT04584112Phase 1

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Completed
NCT02268695Phase 2

Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC

Completed
NCT02961257Phase 3

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel

Completed
NCT03471611Phase 1

Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis

Completed
NCT00082329Phase 2

G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers

Completed
NCT02703779Phase 2

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

Completed
NCT03042780Phase 2

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Terminated
NCT02611492Phase 3

A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults

Unknown
NCT01025284Phase 2

A Study for Participants With Small-Cell Lung Cancer

Completed
NCT00245037Phase 1

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Completed
NCT00741780

Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).

Completed
NCT00741325

Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).

Completed
NCT01750866Phase 2

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer

Withdrawn
NCT01161550Phase 1

Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML

Completed

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19